Skip to content
DataLookout
Start free
Menu

TRIUMPH-8NCT07232719

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

StatusActive, Not Recruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 16 words
    • Study completion pushed from Jul 2027 to Jun 2028
    • Primary completion date: Jul 2027 to Jun 2027
    • Site details revised at 2 of 31 sites
  2. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 31 of 31 sites
    v4
  3. Site details revised at 25 of 31 sitesv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 32 to 31
    • Start date changed from estimate of Dec 2025 to Nov 17, 2025
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Percent Change from Baseline in Body Weight
Timeframe: Baseline, Week 56

Secondary (4)

Change from Baseline in Systolic Blood Pressure
Change from Baseline in Waist Circumference
Percent Change from Baseline in Non-High-Density Lipoprotein (HDL) Cholesterol
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC)

Arms and interventions

Retatrutide Dose 1Experimental

Participants will receive retatrutide subcutaneously (SC)

Retatrutide Dose 2Experimental

Participants will receive retatrutide SC

PlaceboPlacebo comparator

Participants will receive placebo SC

Drugs: Retatrutide, Placebo

Sites

31 sites in 2 countries

United States 19, United Kingdom 12